• Imaging agents

Vizamyl Generic Name & Formulations

General Description

Flutemetamol F 18 (150MBq/mL [4.05mCi/mL]); soln for IV inj; contains polysorbate 80.

Pharmacological Class

Radioactive diagnostic agent.

How Supplied

Multi-dose vials (30mL)—1


Generic Availability


Vizamyl Indications


For PET imaging of the brain to estimate β-amyloid neuritic plaque density in adults with cognitive impairment who are being evaluated for Alzheimer’s Disease (AD) and other causes of cognitive decline. As an adjunct to other diagnostic evaluations.

Limitations of Use

A positive Vizamyl scan does not establish a diagnosis of AD or other cognitive disorder. Safety and efficacy not established for predicting development of dementia or other neurologic conditions, or for monitoring responses to therapies.

Vizamyl Dosage and Administration


See full labeling. Give 185MBq (5mCi), max 20μg mass dose, as a single IV bolus in a total volume of ≤10mL within 40 seconds. Follow injection with 5–15mL IV flush of 0.9% sterile NaCl. Starting 60–120mins after IV inj, acquire a 10–20min PET image. The radiation absorbed dose from 185MBq (5mCi) dose is 5.92mSv.


Not established.

Vizamyl Contraindications


Allergy to polysorbate 80.

Vizamyl Boxed Warnings

Not Applicable

Vizamyl Warnings/Precautions


Risk of radiation exposure. Should only be used by trained and experienced physicians in the safe use and handling of radioactive materials to minimize radiation exposure. Risk of image misinterpretation and other errors. Perform image interpretation independently of patient's clinical information. Pregnancy. Nursing mothers: not recommended, or temporarily interrupt for 24hrs after Vizamyl exposure.

Vizamyl Pharmacokinetics

See Literature

Vizamyl Interactions

Not Applicable

Vizamyl Adverse Reactions

Adverse Reactions

Flushing, headache, increased blood pressure, nausea, dizziness; hypersensitivity reactions.

Vizamyl Clinical Trials

See Literature

Vizamyl Note

Not Applicable

Vizamyl Patient Counseling

See Literature